Yi Sui

Dr. Yi Sui


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
SLShuo Liu
Shuo Liu
YSYa-Ping Sun
Ya-Ping Sun
XGXu-Ling Gao
Xu-Ling Gao
YSYi Sui
Yi Sui
Alzheimer’s disease is the most common cause of dementia. It is an increasingly serious global health problem and has a significant impact on individuals and society. However, the precise cause of Alzheimer’s disease is still unknown. In this study, 11,748 Web-of-Science-indexed manuscripts regarding Alzheimer’s disease, all published from 2015 to 2019, and their 693,938 references were analyzed. A document co-citation network map was drawn using CiteSpace software. Research frontiers and development trends were determined by retrieving subject headings with apparent changing word frequency trends, which can be used to forecast future research developments in Alzheimer’s disease.

13 August 2018 in Medical Science Monitor
Verified
Journal Article
Closed access
PDF file
YJYang Jiang
Yang Jiang
BXBin Xu
Bin Xu
JCJing Chen
Jing Chen
YSYi Sui
Yi Sui
LRLi Ren
Li Ren
XSXiaohong Sun
Xiaohong Sun
BACKGROUND:Alzheimer’s disease (AD) results in cognitive impairment. The calcium voltage-gated channel subunit alpha-1 C CACNA1C gene encodes an alpha-1 C subunit of L-type calcium channel (LTCC). The aim of this study was to investigate the role o...

1 January 2018 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
XSXiao-Hong Sun
Xiao-Hong Sun
YDYu-Xia Dong
Yu-Xia Dong
HZHui-Yu Zhang
Hui-Yu Zhang
HLHui-Yuan Li
Hui-Yuan Li
PLPei-Hui Liu
Pei-Hui Liu
YSYi Sui
Yi Sui
The APPSwe/PSEN1dE9 (APP/PS1) transgenic mouse model is an Alzheimer’s disease mouse model exhibiting symptoms of dementia, and is commonly used to explore pathological changes in the development of Alzheimer’s disease. Previous clinical autopsy and imaging studies suggest that Alzheimer’s disease patients have white matter and oligodendrocyte damage, but the underlying mechanisms of these have not been revealed. Therefore, the present study used APP/PS1 mice to assess cognitive change, myelin loss, and corresponding changes in oligodendrocytes, and to explore the underlying mechanisms. Morris water maze tests were performed to evaluate cognitive change in APP/PS1 mice and normal C57BL/6 mice aged 3 and 6 months. Luxol fast blue staining of the corpus callosum and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for myelin basic protein (MBP) mRNA were carried out to quantify myelin damage. Immunohistochemistry staining for NG2 and qRT-PCR for monocarboxylic acid transporter 1 (MCT1) mRNA were conducted to assess corresponding changes in oligodendrocytes. Our results demonstrate that compared with C57BL/6 mice, there was a downregulation of MBP mRNA in APP/PS1 mice aged 3 months. This became more obvious in APP/PS1 mice aged 6 months accompanied by other abnormalities such as prolonged escape latency in the Morris water maze test, shrinkage of the corpus callosum, upregulation of NG2-immunoreactive cells, and downregulation of MCT1 mRNA. These findings indicate that the involvement of early demyelination at 3 months and the oligodendrocyte dysfunction at 6 months in APP/PS1 mice are in association with Alzheimer’s disease pathogenesis.


1 April 2024 in Stroke
Verified
Journal Article
Closed access
YZYang Zhang
Yang Zhang
TLTian Lv
Tian Lv
Thanh N NguyenThanh N Nguyen
Thanh N Nguyen
SWSimiao Wu
Simiao Wu
ZLZhi Li
Zhi Li
YSYi Sui
Yi Sui
BACKGROUND: The efficacy of thrombolysis (IVT) in minor stroke (National Institutes of Health Stroke Scale score, 0–5) remains inconclusive. The aim of this study is to compare the effectiveness and safety of IVT with best medical therapy (BMT) by means of a systematic review and meta-analysis of randomized controlled trials and observational studies. METHODS: We searched the PubMed, Embase, Cochrane Library, and Web of Science databases to obtain articles related to IVT in minor stroke from inception until August 10, 2023. The primary outcome was an excellent functional outcome, defined as a modified Rankin Scale score of 0 or 1 at 90 days. The associations were calculated for the overall and preformulated subgroups by using the odds ratios (ORs). This study was registered with PROSPERO (CRD42023445856). RESULTS: A total of 20 high-quality studies, comprised of 13 397 patients with acute minor ischemic stroke, were included. There were no significant differences observed in the modified Rankin Scale scores of 0 to 1 (OR, 1.10 [95% CI, 0.89–1.37]) and 0 to 2 (OR, 1.16 [95% CI, 0.95–1.43]), mortality rates (OR, 0.67 [95% CI, 0.39–1.15]), recurrent stroke (OR, 0.89 [95% CI, 0.57–1.38]), and recurrent ischemic stroke (OR, 1.09 [95% CI, 0.68–1.73]) between the IVT and BMT group. There were differences between the IVT group and the BMT group in terms of early neurological deterioration (OR, 1.81 [95% CI, 1.17–2.80]), symptomatic intracranial hemorrhage (OR, 7.48 [95% CI, 3.55–15.76]), and hemorrhagic transformation (OR, 4.73 [95% CI, 2.40–9.34]). Comparison of modified Rankin Scale score of 0 to 1 remained unchanged in subgroup patients with nondisabling deficits or compared with those using antiplatelets. CONCLUSIONS: These findings indicate that IVT does not yield significant improvement in the functional prognosis of patients with acute minor ischemic stroke. Additionally, it is associated with an increased risk of symptomatic intracranial hemorrhage when compared with the BMT. Moreover, IVT may not have superiority over BMT in patients with nondisabling deficits or those using antiplatelets.

25 March 2022 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
YZYao Zhang
Yao Zhang
MOMenglu Ouyang
Menglu Ouyang
JQJianting Qiu
Jianting Qiu
XCXiaopan Cao
Xiaopan Cao
BXBing Xu
Bing Xu
YSYi Sui
Yi Sui